Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioItaLEE: Molecular Features of HR+ HER2- Advanced Breast Cancer on Ribociclib+Letrozole and Alpelisib+Fulvestrant
NCT03439046Phase 3Terminated
- Sponsor
- Novartis
- Start
- Feb 2018
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ribociclib, alpelisib in breast cancer, sponsored by Novartis. Started Feb 2018; status: terminated.
02
Drugs
ribociclibalpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03439046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03439046.